- In a bid to ensure important medicines are produced in the U.S., the Trump administration is enlisting two manufacturers previously known best for making cameras and film to help manufacture drug ingredients as well as experimental coronavirus vaccine candidates.
- On Tuesday, the U.S government announced plans to loan Eastman Kodak $765 million under the Defense Production Act, funding a pivot by the company to manufacture active pharmaceutical ingredients for generic drugs. The Wall Street Journal first reported the news.
- News of the loan came one day after the Fujifilm Diosynth Biotechnologies, a joint venture between Japan’s Fujifilm and Mitsubishi, was tapped to support coronavirus vaccine manufacturing through a $265 million contract between the Biomedical Advanced Research and Development Authority and Texas A&M University.
The Trump administration has made onshoring drug supply chains a priority, and is turning to some unusual candidates to help accomplish its goal.
Rochester, New York-based Kodak famously led the film and camera industry for decades but failed to establish a similar position in digital photography, leading to a downward slide in its business and a bankruptcy filing in 2012.
The $765 million loan from the federal government would jumpstart a shift to making drug ingredients, something Fujifilm has done successfully with its contract manufacturing arm Fujifilm Diosynth. Kodak will use the funds to repurpose its plants in Rochester and St. Paul, Minnesota.
The loan comes from the International Development Finance Corporation and is the first to target drug manufacturing under the Defense